Reveal Logo

The REVEAL Trial is a clinical research trial targeting the Melanoma patient population.

[two_third]

  • Mary Crowley Medical Research Center
  • Recruiting
  • Dallas, Texas, United States, 75201

Principal Investigator: John Nemunaitis, MD

Please complete the information request form and you will be contacted once the investigational site is open to recruiting.
If you prefer not to submit a contact form, please CLICK HERE to send an email. Please include your name, city and state in the message and your information will be sent to the nearest investigational site.
By submitting your contact information, you agree to have your information used for the purpose of obtaining information on clinical trials. Your contact information will only be provided by BioNews Services, a third party vendor, to study doctors and their teams who are enrolling patients into clinical trials. Your contact information will not be sold, shared with any other third parties, or used for any other purpose. After a period of 3 years, your contact information will be destroyed, unless you have provided written permission otherwise.

[/two_third]
[one_third_last]

Full Name *

Email *

Phone *

Message (optional)

[/one_third_last]

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label, Multicenter, Dose-escalation, Phase 1b/2 Study of the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of RTA 408 in Combination With Ipilimumab in the Treatment of Patients With Unresectable or Metastatic Melanoma
Ages Eligible for Study: 18 Years and older
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

  1. Be ≥18 years of age;
  2. Have advanced, unresectable (Stage III) or metastatic (Stage IV) melanoma;
  3. Have received no prior treatment with ipilimumab;
  4. Have discontinued previous treatments for cancer;
  5. Have discontinued previous experimental therapies for a minimum of 28 days;
  6. Be able to swallow capsules.

Exclusion Criteria:

  1. Have prior malignancy active within the previous 2 years;
  2. Have any active autoimmune disease or a history of known or suspected autoimmune disease;
  3. History of brain metastases that meet certain conditions;
  4. History of specific cardiovascular abnormalities;
  5. Have known active fungal, bacterial, and/or viral infection, including human immunodeficiency virus (HIV) or hepatitis virus (A,B, or C).

Leave a Comment

Your email address will not be published. Required fields are marked *